CERS

CERUS CORP (CERS) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction in platelets, plasma, and red blood cells. The company operates in one reportable segment and relies on product sales and government contracts (BARDA, DoD) for revenue. As of April 16, 2026, there were approximately 200.4 million shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 23% year-over-year, driven by a 24% increase in product revenue (primarily U.S. disposable platelet kit and IFC sales) and an 11% increase in government contract revenue.
• Profitability Improvement: Net loss narrowed significantly from $7.7 million in Q1 2025 to $1.6 million in Q1 2026. Loss from operations improved from $(5.9) million to $(0.4) million.
• Gross Margin Compression: Product gross margin decreased to 52% from 59% in the prior year, attributed to inflationary pressures, tariffs, higher freight charges, and the absence of capitalized inventoriable charges that benefited the prior year.
• Expense Management: R&D expenses decreased 12% to $14.5 million, and SG&A expenses decreased 2% to $19.9 million.
• Debt Structure: Total debt increased slightly to $84.8 million. Current debt obligations rose to $52.4 million as the Term Loan began amortizing on April 1, 2026.

Guidance, Outlook, and Risks

• Red Blood Cell (RBC) System: The RBC system remains in development. The company resubmitted its MDR application for the EU after a previous closure due to insufficient data on impurity profiles. The review of the active pharmaceutical ingredient (API) was transferred to the French National Agency for Medicines and Health Products Safety (ANSM). No decision timeline is available.
• Clinical Trials: Enrollment for the U.S. Phase 3 RedeS study was completed in 2025, with trial completion anticipated in the second half of 2026. The company anticipates needing additional clinical data beyond the ReCePI and RedeS studies before FDA PMA submission.
• Government Funding: The 2016 BARDA agreement expires in September 2026. A new 2024 BARDA agreement provides up to $188.4 million in potential funding. The DoD contract value was increased to $25.0 million in July 2025.
• Liquidity: Management believes cash, investments, and government contract funding are sufficient for at least the next 12 months. However, the company expects to continue generating losses and may require additional capital to fund RBC development and commercialization.
• Key Risks:
  • Regulatory delays or failure to obtain CE Mark for the RBC system.
  • Dependence on sole-source supplier Fresenius for manufacturing.
  • Impact of tariffs, inflation, and geopolitical conflicts on supply chain and margins.
  • Concentration of revenue from a few large customers (e.g., American Red Cross).

Investor Verification Checklist

• Verify the status and timeline of the resubmitted MDR application for the RBC system with ANSM.
• Monitor the completion date and topline results of the RedeS Phase 3 clinical trial (expected H2 2026).
• Assess the impact of the Term Loan amortization (starting April 1, 2026) on future cash flow and working capital.
• Review the progress of BARDA funding utilization and the likelihood of exercising remaining options under the 2024 agreement.
• Track gross margin trends given the headwinds from tariffs, freight costs, and inflation.
• Confirm the status of the new LED-based illuminator regulatory approvals in the U.S. and other key markets.